Local co-administration of gene-silencing RNA and drugs in cancer therapy: State-of-the art and therapeutic potential. (April 2017)

• Record Type: Journal Article
• Authors: Larsson, Mikael; Huang, Wei-Ting; Liu, Dean-Mo; Losic, Dusan
• Is Part Of: Cancer treatment reviews. Volume 55(2017)
• Page Start: 128
• Page End: 135
• Publication Date: 2017-04
• Subjects: Drug delivery system -- Combinatory treatment -- Tumor -- Synergy -- RNA -- Therapeutic substance; Cancer -- Periodicals; Cancer -- Treatment -- Periodicals; Neoplasms -- therapy -- Periodicals; Cancer -- Périodiques; Cancer -- Traitement -- Périodiques; Cancer -- Treatment; Electronic journals; Periodicals; 616.99406
• DOI: 10.1016/j.ctrv.2017.03.004
• Languages: English
• ISSNs: 0305-7372

Abstract

Graphical abstract: Highlights: Local co-administration of RNA and drugs is investigated for cancer treatment. Promising tumor suppression in animal models is demonstrated. A young research field that will evolve with advanced formulations. Abstract: Gene-silencing miRNA and siRNA are emerging as attractive therapeutics with potential to suppress any genes, which could be especially useful in combination cancer therapy to overcome multidrug resistant (MDR) cancer. Nanomedicine aims to advance cancer treatment through functional nanocarriers that delivers one or more therapeutics to cancer tissue and cells with minimal off-target effects and suitable release kinetics and dosages. Although much effort has gone into developing circulating nanocarriers with targeting functionality for systemic administration, another alternative and straightforward approach is to utilize formulations to be administered directly to the site of action, such as pulmonary and intratumoral delivery. The combination of gene-silencing RNA with drugs in nanocarriers for localized delivery is emerging with promising results. In this review, the current progress and strategies for local co-administration of RNA and drug for synergistic effects and future potential in cancer treatment are presented and discussed. Key advances in RNA-drug anticancer synergy and localized delivery systems were combined with a review of the available literature on local co-administration of RNA and drug for cancer treatment. It is concluded that advanced delivery systems for local administration of gene-silencing RNA and drug hold potential in treatment of cancer, depending on indication. In particular, there are promising developments using pulmonary delivery and intratumoral delivery in murine models, but further research should be conducted on other local administration strategies, designs that achieve effective intracellular delivery and maximize synergy and feasibility for clinical use.